TICKERNERD
Menu
CGENCGENHealthcare · Biotechnology

CGEN Stock Forecast: Compugen Ltd. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$2.41
0.00% on the day

The 5 Wall Street analysts covering Compugen Ltd. hold a median 12-month price target of $4 — +66.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$228.3M
Ticker Nerd rank
72 / 100
Median analyst target
$4.00
Analysts covering
5
Total return, dividends reinvested
1W
0.0%
1M
+4.8%
YTD
+57.5%
1Y
+66.2%
From 52W high
−22.3%
From 52W low
+81.2%
$1.33
$3.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Compugen Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Momentum
73
Quality
73
Size
67
Value
61
Revisions
50
Volatility
49
Issuance
48
Accruals
21

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26CGENHigh $6.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $4.00Median $4.00High $6.00

The green dot is the last close — the median target sits +66.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 May 2026Leerink PartnersMaintainsOutperform$13 → $5.00
7 Apr 2026Lake StreetInitiatesBuy—
7 Jan 2026HC Wainwright & Co.InitiatesBuy—
21 May 2024Truist SecuritiesMaintainsBuy—
8 Mar 2024Truist SecuritiesMaintainsBuy—
19 Dec 2023StifelMaintainsBuy—
23 Aug 2023Truist SecuritiesReiteratesBuy—
7 Aug 2023EF HuttonReiteratesBuy—
6 June 2023EF HuttonReiteratesBuy—
26 May 2023EF HuttonReiteratesBuy—
24 May 2023EF HuttonReiteratesBuy—
16 May 2023OppenheimerMaintainsOutperform—
28 Feb 2023OppenheimerReiteratesOutperform—
8 Feb 2023JefferiesDowngradeUnderperform—
5 Jan 2023EF HuttonInitiatesBuy—
15 Nov 2022OppenheimerMaintainsOutperform—
23 Aug 2022Truist SecuritiesMaintainsBuy—
8 Aug 2022JMP SecuritiesMaintainsMarket Outperform—
8 Aug 2022OppenheimerMaintainsOutperform—
5 Aug 2022JefferiesDowngradeHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Compugen Ltd. (CGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
6.3×

Cheaper than 65% of US stocks

Price / sales
3.1×

Cheaper than 41% of US stocks

Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
3.5×

Cheaper than 55% of US stocks

Growth & margins
Revenue growth (YoY)
107.0%

Higher than 93% of US stocks

Earnings growth (YoY)
107.0%

Higher than 85% of US stocks

Gross margin
−3.5%

Higher than 4% of US stocks

Operating margin
−339.6%

Higher than 9% of US stocks

Net margin
47.6%

Higher than 96% of US stocks

Returns & dividend
Return on equity
50.6%

Higher than 93% of US stocks

Return on assets
15.5%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGENCompugen Ltd.$228.3M
72
CUECue Biopharma, Inc.$233.5M
48
ARCTArcturus Therapeutics Holdings, Inc.$233.8M
58
TARAProtara Therapeutics, Inc.$234.6M
38
RNAAtrium Therapeutics, Inc.$219.7M
6
IMUXImmunic, Inc.$218.8M
40
CNXUConexeu Sciences, Inc.$238.1M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Compugen Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGEN news & analysis

Compugen: Better Runway Ahead Of MAIA

Seeking Alpha · 7 Aug 2026positive

The article notes that Compugen has improved its cash runway to support operations into 2029, which should carry the company through the interim analysis of the MAIA trial. It identifies MAIA as the main value driver and suggests that a positive randomized readout could help validate COM701 and the broader PVRIG approach.

Why it matters — A longer runway reduces near-term financing risk and better positions CGEN to reach its key MAIA clinical data milestone.

Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 3 Aug 2026neutral

Seeking Alpha published the transcript of Compugen Ltd.'s (CGEN) Q2 2026 earnings call. The item is a transcript of the company's second-quarter 2026 earnings call.

Why it matters — A CGEN watcher would care because earnings-call transcripts provide management's commentary on quarterly results and company outlook.

Compugen Q2 Earnings Call Highlights

MarketBeat · 3 Aug 2026positive

Compugen reported that its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancement of partner-led programs with AstraZeneca and Gilead, and a cash runway projected to extend into 2029.

Why it matters — A CGEN watcher would care because the update signals ongoing clinical progress, strong partnership execution, and financial stability extending into 2029.

Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 3 Aug 2026negative

Compugen reported a Q2 loss of $0.07 per share, matching the Zacks Consensus Estimate and narrowing from a loss of $0.08 per share in the same quarter last year. The company's results missed revenue estimates.

Why it matters — The quarterly results provide the latest snapshot of Compugen's financial performance, including whether the company is making progress toward narrowing its losses.

Compugen Reports Second Quarter 2026 Results

PRNewsWire · 3 Aug 2026positive

Compugen reported second-quarter 2026 results, stating its COM701 MAIA-ovarian trial is progressing as planned with interim progression-free survival data expected by Q1 2027. The company also highlighted a trial-in-progress poster presented at ESMO Gynaecological Cancers Congress 2026, new data from partner AstraZeneca at ASCO 2026, continued progress in the Gilead-partnered GS-0321 Phase 1 trial, and a cash runway expected to fund operations into 2029.

Why it matters — CGEN watchers would care because the update confirms continued advancement of key pipeline programs and partner collaborations while the company maintains a solid financial position.

FAQ

Frequently asked questions about CGEN stock

What is the CGEN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Compugen Ltd. have a median 12-month price target of $4, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGEN stock a buy right now?

Of the 5 analysts covering Compugen Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Compugen Ltd. 72 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGEN?

As at 15 Aug 2026, Compugen Ltd. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will CGEN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +66.0% from the last close, and Ticker Nerd's factor model ranks Compugen Ltd. 72 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGEN stock forecast for 2030?

No analyst covering Compugen Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has CGEN stock performed over the past year?

Compugen Ltd. returned +66.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Compugen Ltd. do?

Compugen Ltd. is a clinical-stage cancer immunotherapy company pioneering computational target discovery powered by AI/ML.

What is the latest news on CGEN?

The most recent item we track (Seeking Alpha, 7 Aug 2026): "Compugen: Better Runway Ahead Of MAIA". The article notes that Compugen has improved its cash runway to support operations into 2029, which should carry the company through the interim analysis of the MAIA trial. It identifies MAIA as the main value driver and suggests that a positive randomized readout could help validate COM701 and the broader PVRIG approach.

Company

About Compugen Ltd.

Compugen Ltd. is a clinical-stage cancer immunotherapy company pioneering computational target discovery powered by AI/ML. It utilizes its proprietary Unigen™ platform, a predictive AI/ML-powered computational discovery tool, to identify novel drug targets and biological pathways for developing immuno-oncology therapies. The company advances wholly owned clinical programs such as COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody in Phase 1 for platinum-resistant ovarian cancer and maintenance therapy in relapsed cases, and COM902, an Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 for solid tumors. Compugen also maintains partnered programs, including bispecific antibodies with AstraZeneca featuring the TIGIT component from COM902, and GS-0321 (formerly COM503), a high-affinity anti-IL-18 binding protein antibody licensed to Gilead for Phase 1 development in advanced solid malignancies. Its pipeline extends to early-stage immuno-oncology research programs targeting new mechanisms to activate the immune system against cancer and overcome resistance. Founded in Israel and headquartered there with offices in San Francisco, California, Compugen Ltd. plays a key role in advancing differentiated antibody therapies in the oncology sector.

CEO Dr. Eran Ophir Ph.D. · 75 employees · Israel · https://cgen.com